April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors
Author Affiliations & Notes
  • Scott E. Woodman
    Melanoma Medical Oncology,
    M D Anderson Cancer Center, Houston, Texas
  • Xiaoxing Yu
    Melanoma Medical Oncology,
    M D Anderson Cancer Center, Houston, Texas
  • Chandrani Chattopadhyay
    Melanoma Medical Oncology,
    M D Anderson Cancer Center, Houston, Texas
  • Michelle Williams
    Pathology,
    M D Anderson Cancer Center, Houston, Texas
  • Nancy Poindexter
    Melanoma Medical Oncology,
    M D Anderson Cancer Center, Houston, Texas
  • Dan S. Gombos
    Section of Ophthalmology,
    M D Anderson Cancer Center, Houston, Texas
  • Martine J. Jager
    Ophthalmology, Leiden University Med Center, Leiden, The Netherlands
  • Elizabeth Grimm
    Melanoma Medical Oncology,
    M D Anderson Cancer Center, Houston, Texas
  • Bita Esmaeli
    Section of Ophthalmology,
    M D Anderson Cancer Center, Houston, Texas
  • Footnotes
    Commercial Relationships  Scott E. Woodman, Glaxo Smith Kline (F); Xiaoxing Yu, Glaxo Smith Kline (F); Chandrani Chattopadhyay, None; Michelle Williams, None; Nancy Poindexter, None; Dan S. Gombos, None; Martine J. Jager, None; Elizabeth Grimm, None; Bita Esmaeli, None
  • Footnotes
    Support  American Society of Clinical OncologyYoung Investigator Award, NIH K12 CA088084
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1441. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Scott E. Woodman, Xiaoxing Yu, Chandrani Chattopadhyay, Michelle Williams, Nancy Poindexter, Dan S. Gombos, Martine J. Jager, Elizabeth Grimm, Bita Esmaeli; GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1441.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Activating GNAQ or GNA11 mutations have been identified in approximately 85% of uveal melanoma tissues. The MEK/MAPK and PI3K/AKT pathways mediate GNAQ and GNA11 growth and survival signaling under normal conditions. The purpose of this study was to test the sensitivity of uveal melanoma cell lines to combination treatment with clinically relevant MEK and PI3K small molecule inhibitors.

Methods: : The GNAQ/11 mutant (MUT) and wild-type (WT) status of eight uveal melanoma cell lines was determined using standard sequencing approaches. Concentration and time-course western blot experiments were used to determine the optimal conditions for MEK inhibitor (MEKi) or PI3K inhibitor (PI3Ki) treatment using GSK1120212 and GSK2126458, respectively. Cell proliferation assays were performed to determine the relative sensitivity of MUT vs. WT cells to MEKi or PI3Ki. Cell cycle analysis was performed to determine the relative percentages of cells in each stage before and after MEKi and/or PI3Ki treatment. Annexin/Propidium-iodide staining was determined by flow cytometry to assess the frequency of apoptotic cells before and after MEKi and/or PI3Ki treatment.

Results: : MEKi treatment resulted in early and sustained loss of MAPK phosphorylation beginning at 10 nM and PI3Ki treatment resulted in early and sustained loss of AKT phosphorylation beginning at 1 nM in both MUT and WT uveal melanoma cell lines. Both MEKi and PI3Ki treatment induced G1 cell cycle arrest in both MUT and WT cells. However, neither MEKi nor PI3Ki treatment induced apoptotic cell death in MUT or WT cells. The combination of MEKi + PI3Ki also failed to induce apoptotic death in WT cells. Conversely, the combination of MEKi + PI3Ki induced a marked increase (40-60% of cells) in the subG0 cellular fraction of MUT cells consistent with apoptotic death at 48 hrs. In addition Annexin V staining was markedly increased MUT cells after combination treatment.

Conclusions: : These results suggest that uveal melanoma cells with driver mutations in GNAQ/11 are highly dependent on the MEK/MAPK and PI3K/AKT pathways for growth and survival. Combination MEKi + PI3Ki small molecule treatment may be an effective therapeutic strategy for the majority of metastatic uveal melanoma patients.

Keywords: melanoma • signal transduction: pharmacology/physiology • genetics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×